SCHEMBL2865230

SCHEMBL2865230

O=C(Cl)c1ccc(Cc2ccc(OCc3ccccc3)cc2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.52
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
KMT2A Q03164 1/20 0.50
HPGD P15428 1/20 0.49
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
NR4A1 P22736 1/20 0.49
NR4A3 Q92570 1/20 0.49
PTGER1 P34995 1/20 0.48
HRH3 Q9Y5N1 2/20 0.48
MAOB P27338 1/20 0.47
PARP10 Q53GL7 1/20 0.47
PTGS1 P23219 2/20 0.46
PTGS2 P35354 2/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC6A3 Q01959 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29130679 0.86 ALOX5 (0.44) MEN1NPC1KMT2AHPGDPTGER1
SCHEMBL2871061 0.85 SRD5A2 (0.51) FFAR1FFAR4SRD5A2PPARGPPARA
SCHEMBL2871257 0.84 NR4A2 (0.49) NR4A2MEN1NPC1KMT2AHPGD
SCHEMBL2864616 0.82 POLB (0.46) NPC1HPGDPARP10CYP2C19
SCHEMBL2865052 0.82 SRD5A2 (0.44) NR4A2HPGDFFAR1FFAR4SRD5A2
SCHEMBL2864886 0.80 KDM4E (0.49) LMNACYP1A2HIF1AHDAC6S1PR5
SCHEMBL2863521 0.80 MEN1 (0.40) MEN1KMT2APARP10
SCHEMBL2863556 0.77 TP53 (0.48) CYP1A2HIF1AHDAC6S1PR5
SCHEMBL2871140 0.77 FFAR4 (0.47) FFAR1FFAR4SRD5A2
SCHEMBL2869145 0.75 MAPT (0.46) MEN1NPC1KMT2AHPGDPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691898-B2 Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101072783-A Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-11-14 CN disclosed
EP-1813620-A1 PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES Kotobuki Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia NR0B1, NR0B2, PTH1R NR4A2 89/4885MEN1 1000/4885NPC1 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.